Lipella Pharmaceuticals is Pharmaceuticals in United States that focus on urine-based diagnostics business. Founded in 2005. They cover business area such as developer, novel drug, treatment, surveillance, imaging, patient, a history, transitional cell carcinoma, pharmaceutical asset, urinary bladder condition, urine-base diagnostic, physician, avail medicine, therapy, area, unmet medical need.
2005
( 19 years old in 2024 )
Urine-based Diagnostics
-
7800 Susquehanna Street
Suite 505
Pittsburgh, PA 15208
United States
Private
developernovel drugtreatmentsurveillanceimagingpatienta historytransitional cell carcinomapharmaceutical asseturinary bladder conditionurine-base diagnosticphysicianavail medicinetherapyareaunmet medical need
* We use standard office opening hours in near Lipella Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Lipella Pharmaceuticals is Pharmaceuticals business from United States that founded in 2005 (19 years old in 2024), Lipella Pharmaceuticals business is focusing on Urine-based Diagnostics.
Lipella Pharmaceuticals headquarter office and corporate office address is located in 7800 Susquehanna Street Suite 505 Pittsburgh, PA 15208 United States.
Lipella Pharmaceuticals was founded in United States.
In 2024, Lipella Pharmaceuticals is currently focus on urine-based diagnostics sector.
Above is snippet of Google Trends for "urine-based diagnostics" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Lipella Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
